High levels of CLDN9 transcripts clearly indicate resistance to chemotherapies in all breast cancer subtypes, including triple-negative breast cancers (TNBC), other than Her-2-positive breast cancers. This evidence concerns the gene CLDN9 and triple-negative breast carcinoma.